To investigate the correlation between the perifoveal capillary blood flow velocity (BFV) and the vitreous level of pigment epithelium-derived factor (PEDF) in patients with branch retinal vein occlusion (BRVO) and macular edema. In a retrospective interventional study of patients with BRVO and macular edema, undiluted vitreous specimens were obtained from 12 eyes of 12 patients. The level of PEDF was then measured in vitreous samples by an enzyme-linked immunosorbent assay. Before vitreous fluid sampling, perifoveal capillary BFV was measured by fluorescein angiography with a scanning laser ophthalmoscope and the tracing method. Subsequently, the relationship between perifoveal capillary BFV and the vitreous level of PEDF was investigated. There was a significant positive correlation between BFV and the vitreous level of PEDF in the 12 patients (ρ = 0.75, p = 0.013). The vitreous level of PEDF may influence macular microcirculation in patients with BRVO and macular edema.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10792-012-9584-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integration of Optical Coherence Tomography Images and Real-Life Clinical Data for Deep Learning Modeling: A Unified Approach in Prognostication of Diabetic Macular Edema.
J Biophotonics
December 2024
Medical Faculty, Ophthalmology Department, University of Health Sciences, Istanbul, Türkiye.
The primary ocular effect of diabetes is diabetic retinopathy (DR), which is associated with diabetic microangiopathy. Diabetic macular edema (DME) can cause vision loss for people with DR. For this reason, deciding on the appropriate treatment and follow-up has a critical role in terms of curing the disease.
View Article and Find Full Text PDFComparison of intravitreal anti-VEGF agents and oral carbonic anhydrase inhibitors in the treatment of cystoid macular edema secondary to retinitis pigmentosa.
Front Pharmacol
December 2024
Shenzhen Eye Hospital, Shenzhen Eye Institute, Shenzhen, Guangdong, China.
Purpose: To compare the efficacy of intravitreal antivascular endothelial growth factor (anti-VEGF) agents with oral carbonic anhydrase inhibitors (CAIs) in treating cystoid macular edema (CME) secondary to retinitis pigmentosa (RP).
Methods: This retrospective study analyzed 98 patients (98 eyes) with RP-CME: 47 (48.0%) received intravitreal anti-VEGF agents (Ranibizumab or Bevacizumab) and 51 (52.
How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema.
BMC Ophthalmol
December 2024
Genentech, Inc, South San Francisco, CA, USA.
Background: Intravitreal anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular oedema (DME) may begin with several initial monthly doses. Characteristics, treatment patterns and outcomes were compared for eyes with DME that did and did not receive such initial doses.
Methods: This was a retrospective database study using American Academy of Ophthalmology Intelligent Research in Sight Registry data (01/01/15-31/12/20; index period).
Injectable Intravitreal Fluocinolone Acetonide Implant for Chronic Postoperative CME in the Presence of Silicone Oil Tamponade.
Retin Cases Brief Rep
October 2024
Texas Retina Associates, Dallas, Texas.
Purpose: This report describes the use of the injectable intravitreal fluocinolone acetonide 0.18mg implant (FAI) for chronic postoperative cystoid macular edema (CME) in an eye with a silicone oil-filled vitreous cavity.
Methods: A retrospective chart review was performed including surgical, clinical, and imaging data.
The introduction of faricimab, a drug targeting both vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2, has enabled the implementation of the highly effective dual inhibition strategy in real clinical practice for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), both previously treated with intravitreal injections and newly diagnosed. This article presents a series of 11 clinical cases involving patients with nAMD and DME who received loading doses of faricimab and continued ophthalmological observation. Among them, three patients with nAMD and two with DME were treatment-naïve, while the others were switched from alternative therapies to faricimab.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!